PLOD2 (procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2), also known as lysyl hydroxylase 2 (LH2), is an enzyme encoded by the PLOD2 gene. It plays a critical role in collagen biosynthesis by catalyzing the hydroxylation of lysine residues in collagen telopeptides, a post-translational modification essential for the formation of stable collagen cross-links. This process influences collagen fibril organization and tissue mechanical properties. PLOD2 is primarily expressed in connective tissues, bones, and organs rich in collagen, such as skin and tendons. Dysregulation of PLOD2 has been implicated in pathological conditions, including cancer metastasis, fibrosis, and connective tissue disorders like Bruck syndrome.
PLOD2 antibodies are immunological tools designed to detect and quantify PLOD2 protein expression in research settings. They are widely used in studies exploring tumor microenvironment remodeling, as PLOD2 overexpression in cancer cells promotes collagen cross-linking, facilitating invasion and metastasis. These antibodies are also applied in fibrosis research, where aberrant PLOD2 activity contributes to excessive collagen deposition. Available in formats like monoclonal or polyclonal antibodies, they support techniques such as Western blotting, immunohistochemistry, and immunofluorescence. Commercial PLOD2 antibodies are often validated for specificity and sensitivity, aiding in mechanistic studies of collagen-related diseases and potential therapeutic targeting. Their utility extends to biomarker discovery and preclinical drug development.